As on Thursday, 10x Genomics Inc (NASDAQ: TXG) got off with the flyer as it spiked 2.95% to $36.35, before settling in for the price of $35.31 at the close. Taking a more long-term approach, TXG posted a 52-week range of $33.79-$63.57.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
The company of the Healthcare sector’s yearbook sales growth during the past 5- year span was recorded 35.76%. Meanwhile, its Annual Earning per share during the time was -13.04%. Nevertheless, stock’s Earnings Per Share (EPS) this year is 27.69%. This publicly-traded company’s shares outstanding now amounts to $105.04 million, simultaneously with a float of $98.01 million. The organization now has a market capitalization sitting at $4.33 billion. At the time of writing, stock’s 50-day Moving Average stood at $41.59, while the 200-day Moving Average is $46.25.
10x Genomics Inc (TXG) Ownership Facts and Figures
Another important factor to analyze is how key investors are playing towards the stock of the Health Information Services industry. 10x Genomics Inc’s current insider ownership accounts for 17.75%, in contrast to 76.01% institutional ownership. According to the most recent insider trade that took place on Mar 04 ’24, this organization’s Chief Executive Officer sold 4,660 shares at the rate of 44.00, making the entire transaction reach 205,021 in total value, affecting insider ownership by 842,900. Preceding that transaction, on Feb 22 ’24, Company’s Chief Executive Officer sold 2,821 for 46.34, making the whole transaction’s value amount to 130,737. This particular insider is now the holder of 847,560 in total.
10x Genomics Inc (TXG) Earnings and Revenue Records
If we go through the results of last quarter, which was made public on 12/30/2023, the company posted -$0.41 earnings per share (EPS) for the quarter, coming under the agreed prediction (set at -$0.36) by -$0.05. Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.48 per share during the current fiscal year.
10x Genomics Inc’s EPS increase for this current 12-month fiscal period is 27.69% and is forecasted to reach -0.92 in the upcoming year.
10x Genomics Inc (NASDAQ: TXG) Trading Performance Indicators
Let’s observe the current performance indicators for 10x Genomics Inc (TXG). It’s Quick Ratio in the last reported quarter now stands at 4.11. The Stock has managed to achieve an average true range (ATR) of 1.55. Another valuable indicator worth pondering is a publicly-traded company’s price to sales ratio for trailing twelve months, which is currently 7.00.
In the same vein, TXG’s Diluted EPS (Earnings per Share) trailing twelve months is recorded -2.18, a figure that is expected to reach -0.50 in the next quarter, and analysts are predicting that it will be -0.92 at the market close of one year from today.
Technical Analysis of 10x Genomics Inc (TXG)
Through scrutinizing the latest numbers posted by the [10x Genomics Inc, TXG], it can be observed that its last 5-days Average volume of 1.17 million was lower the volume of 1.41 million, it posted the year before. During the previous 9 days, stock’s Stochastic %D was recorded 39.45% While, its Average True Range was 1.47.
Raw Stochastic average of 10x Genomics Inc (TXG) in the period of the previous 100 days is set at 6.18%, which indicates a major fall in contrast to 39.89% during the last 2-weeks. If we go through the volatility metrics of the stock, In the past 14-days, Company’s historic volatility was 39.30% that was lower than 46.74% volatility it exhibited in the past 100-days period.
